Impact of multidisciplinary tumour board in the management of ovarian carcinoma in the first‐line setting. Exhaustive analysis from the Rhone‐Alpes region

Objective Epithelial ovarian cancer (EOC) is a poor prognosis disease partly linked to diagnosis at an advanced stage. The quality of care management is a factor that needs to be explored, more specifically optimal organisation of first‐line treatment. Methods A retrospective study, dealing with all...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of cancer care 2020-11, Vol.29 (6), p.e13313-n/a
Hauptverfasser: Ferraioli, Domenico, Bally, Olivia, Meeus, Pierre, Benayoun, David, Bakrin, Naoual, De Saint Hilaire, Pierre, Beal Ardisson, Dominique, Provençal, Jocelyne, Barletta, Hugues, Mousseau, Mireille, Chauleur, Céline, Verbaere, Sylvain, Knibiehly, Alain, Fuso, Luca, Charreton, Amandine, Devouassoux‐Shisheboran, Mojgan, Chopin, Nicolas, Glehen, Olivier, Labrosse‐Canat, Hélène, Farsi, Fadila, Ray‐Coquard, Isabelle
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Objective Epithelial ovarian cancer (EOC) is a poor prognosis disease partly linked to diagnosis at an advanced stage. The quality of care management is a factor that needs to be explored, more specifically optimal organisation of first‐line treatment. Methods A retrospective study, dealing with all patients diagnosed within the Rhone‐Alpes region with initial diagnosis EOC in 2012, was performed. The aim was to describe the impact of multidisciplinary tumour boards (MTB) in the organisation of care and the consequence on the patient's outcomes. Results 271 EOC were analysed. 206 patients had an advanced EOC. Median progression‐free survival (PFS) is 17.8 months (CI95%, 14.6–21.2) for AOC. 157 patients (57.9%) had a front‐line surgery versus 114 patients (42.1%) interval debulking surgery. PFS for AOC patients with no residual disease is 24.3 months compared with 15.3 months for patients with residual disease (p = .01). No macroscopic residual disease is more frequent in the patients discussed before surgery in MTB compared with patients not submitted before surgery (73% vs. 56.2%, p 
ISSN:0961-5423
1365-2354
DOI:10.1111/ecc.13313